Gossamer Bio, Inc. Stock

Equities

GOSS

US38341P1021

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
0.65 USD +14.34% Intraday chart for Gossamer Bio, Inc. +25.00% -28.77%
Sales 2024 * 114M Sales 2025 * 4.17M Capitalization 147M
Net income 2024 * -71M Net income 2025 * -188M EV / Sales 2024 * 1.88 x
Net Debt 2024 * 67.55M Net Debt 2025 * 127M EV / Sales 2025 * 65.6 x
P/E ratio 2024 *
-1.63 x
P/E ratio 2025 *
-0.86 x
Employees 135
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.05%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Gossamer Bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications CI
Transcript : Chiesi Farmaceutici S.p.A., Gossamer Bio, Inc. - M&A Call
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment RE
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine CI
Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Gossamer Bio Announces Board of Directors Appointments CI
Goldman Sachs Adjusts Price Target on Gossamer Bio to $8 From $9, Maintains Buy Rating MT
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
HC Wainwright Adjusts Price Target on Gossamer Bio to $10 From $5, Keeps Buy Rating MT
Transcript : Gossamer Bio, Inc. - Special Call
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from NASDAQ Biotechnology Index CI
Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer CI
More news
1 day+14.34%
1 week+25.00%
Current month+10.17%
1 month+2.07%
3 months-51.85%
6 months-24.65%
Current year-28.77%
More quotes
1 week
0.53
Extreme 0.5312
0.72
1 month
0.50
Extreme 0.4993
0.72
Current year
0.50
Extreme 0.4993
1.60
1 year
0.45
Extreme 0.4525
1.88
3 years
0.45
Extreme 0.4525
15.20
5 years
0.45
Extreme 0.4525
27.15
10 years
0.45
Extreme 0.4525
27.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 15-10-24
Director of Finance/CFO 49 18-05-06
Chief Tech/Sci/R&D Officer - 23-10-02
Members of the board TitleAgeSince
Chief Executive Officer 65 15-10-24
Director/Board Member 70 17-12-31
Director/Board Member 48 Mar. 10
More insiders
Date Price Change Volume
24-06-21 0.65 +14.34% 11,652,013
24-06-20 0.5685 +4.81% 916,552
24-06-18 0.5424 +4.29% 4,436,079
24-06-17 0.5201 +0.02% 15,763,298

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm EDT

More quotes
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
0.65 USD
Average target price
6.094 USD
Spread / Average Target
+837.50%
Consensus